Currently, fractional flow reserve (FFR) is regarded as a gold-standard invasive method to define lesion-specific ischemia and FFR-guided PCI has been proven to reduce unnecessary revascularization and to enhance patient's clinical outcomes. Therefore, current guidelines recommend FFR measurement for intermediate coronary stenosis when there is no definite evidence of lesion-specific ischemia. However, previous evidences which well demonstrated the benefit of FFR-guided strategy were mostly generated from patients with stable coronary artery disease.4 FFR may be overestimated and the hemodynamic relevance of a coronary stenosis underestimated in patients with acute coronary syndrome (ACS).Its role in ACS patients still needs to be defined although several studies have recently published addressing the value of FFR-guided PCI in ACS. In fact, recent evidence suggests that culprit lesions of patients presenting with a non-ST-segment elevation myocardial infarction that were deferred based on a "negative" FFR have a relatively high event rate, calling into question the use of FFR in that patient population.
STUDY OBJECTIVE 1. To evaluate the impact of FFR on decision for PCI in ACS patients 2. To assess the long term prognosis of deferring PCI based on FFR value in non-culprit lesion; defying the cut-off value of FFR for PCI in the non-culprit lesion of ACS patients 3. To identify the relation between OCT findings and FFR value in culprit and non-culprit lesions of ACS patients 4. To compare the long term prognosis of PCI or deferring PCI based on FFR value in non-culprit lesion of ACS patients 5. To identify OCT findings to predict the lesion progression in deferred lesions. 6. To assess the long term prognosis of post-PCI FFR value in the culprit lesion of NSTE-ACS patients 7. To assess the efficacy of routine use of FFR to guide PCI in ACS patients; angiographically guidance versus FFR guidance
Study Type
OBSERVATIONAL
Enrollment
500
Functional assessement of anatomical stenosis of coronary artery
St.Vincent's Hospital
Suwon, Gyeonggido, South Korea
Uijeongbu St.Mary's Hospital
Uijeongbu-si, Gyeonggido, South Korea
Daejeon St.Mary's Hospital
Daejeon, South Korea
Incheon St.Mary's Hospital
Incheon, South Korea
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, South Korea
Rate of Major adverse cardiac events
Rate of the composite of all-cause death, recurrent myocardial infarction
Time frame: 24 months
Rate of Major adverse cardiac events at 1 year
Rate of composite of all-cause death, recurrent myocardial infarction
Time frame: 12 months
Rate of Ischemic events
Rate of the composite of all-cause death, recurrent myocardial infarction, and any repeat revascularization
Time frame: 24 months
Rate of Death
Rate of All cause death and cardiac death
Time frame: 24 months
Rate of Repeat revascularization
Rate of Any repeat revascularization
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.